DR. KENT
CBD GLUCOSAMINE CREAM

Ingredients: AQUA, STEARIC ACID, COCO-CAPRYLATE/CAPRATE, PERSEA GRATISSIMA OIL, DIMETHYL SULFONE, CANNABIS SATIVA BIOMASS EXTRACT, CAPRYLIC/CAPRIC TRIGLYCERIDE, CETEARYL ALCOHOL, GLYCERYL STEARATE, SQUALANE, MENTHOL, CAMPHOR, METHYL SALICYLATE, SODIUM CHONDROITIN SULFATE, GLUCOSAMINE SULFATE, SORBITAN CAPRYLATE, PROPANEDIOL, BENZOIC ACID, EUGENIA CARYOPHYLLUS FLOWER OIL, SODIUM CETEARYL SULFATE, CAPSICUM FRUTESCENS FRUIT EXTRACT, ROSMARINUS OFFICINALIS EXTRACT, BRASSICA CAMPESTRIS SEED OIL, EUGENOL, ISOEUGENOL

HEMP EXTRACT
Cannabis sativa L.

GLUCOSAMINE SULFATE
Glucosamine sulfate

MENTHOL
Mentha × piperita

CAMPHOR
Camphor

Pharma Hemp®
LABORATORIES

SLOVENSKA AKREDITACIJA
SIST EN ISO/IEC 17025
LP-117
The results marked by # relate to non-accredited activity

CERTIFICATE OF ANALYSIS No.: 2021-7177

CLIENT
Pharmahemp d.o.o., Cesta v Gorice 8
1000 Ljubljana, Slovenija

SAMPLE *
DR KENT CBD GLUCOSAMINE CREAM

Sample condition:	SUITABLE	Work order:	2021-105982	Sample received:	15/12/2021
Sample ID:	2150077	Analysis ID:	2021_290	Start of analysis:	15/12/2021
Sample type:	Paste	Method ID:	PHL_RPC_12C	End of analysis:	16/12/2021
Batch No.: *	KCG00521343A	Method SOP:	MET-002-03	Analyst:	Janez Gerdenc

* Information provided by the client.

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV - Cannabidivarin	< LOQ	n/a	
CBDA - Cannabidiolic acid	0.272	0.046	
CBGA - Cannabigerolic acid	< LOQ	n/a	
CBG - Cannabigerol	< LOQ	n/a	
CBD - Cannabidiol	0.323	0.048	
THCV - Tetrahydrocannabivarin	< LOQ	n/a	
CBN - Cannabinol	< LOQ	n/a	
CBC - Cannabichromene	< LOQ	n/a	
THC - Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
THCA - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
8-THC - Δ-8-Tetrahydrocannabinol	< LOQ #	n/a	
CBL - Cannabicyclol	< LOQ #	n/a	

Units and abbreviations: **% w/w** = weight percent, **< LOQ** = below the limit of quantitation (0.03 % w/w), **ND** = not detected, **n/a** = not available.

The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

16/12/2021

Approved by:

mag. Marko Dragan
Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar
Chief Technology Officer

End of Certificate